Abstract: A method of a terminal, according to an exemplary embodiment of the present disclosure, may include: requesting access to a mobile integrated access backhaul (IAB) based on cell search; receiving a tracking area (TA) update procedure stop request message from an Access and Mobility Management Function (AMF) of a core network; and deactivating a TA update procedure based on the TA update procedure stop request message.

Abstract: A method of an integrated access and backhaul (IAB) node may include: receiving, from a target base station, one or more user equipment (UE) context setup request messages including terminal radio resource reconfiguration information; sharing context information including the terminal radio resource reconfiguration information with a source IAB-distributed unit 1 (IAB-DU1); configuring terminal reconfiguration information using the shared context information; and transmitting one or more UE context setup response messages including the terminal reconfiguration information to the target base station in response to the one or more UE context setup request messages.

Abstract: A method of an IAB node may comprise: receiving an RRC message including measurement control information from a base station; transmitting RRC reconfiguration information including the measurement control information to each of a plurality of terminals; receiving a measurement report message including a measurement report generated by each of the plurality of terminals based on the measurement control information from each of the plurality of terminals; and grouping the measurement report messages received from the plurality of terminals into a grouped message report message, and transmitting the grouped measurement report message to the base station according to a grouped measurement reporting periodicity.

Abstract: A wafer processing system includes an optical apparatus including a beam splitter configured to receive a laser beam and to split the laser beam into a first beam in a first state of linear polarization and a second beam in a second state of linear polarization; and a beam delayer configured to delay the second beam so that a pulse of the second beam has a delay time with respect to a pulse of the first beam.

Abstract: A method of controlling an EOP of a powertrain may include determining, by a controller electrically connected to the EOP, whether an oil sloshing phenomenon in which it is difficult for oil to return to a space where an oil intake port of the EOP is positioned may occur while a vehicle is running; and reducing, by the controller, the revolutions per minute (RPM) of the EOP by a predetermined reduced RPM when it is determined that the oil sloshing phenomenon may occur.

Abstract: Disclosed is a composite for forming a coacervate interfacial film. The composite for forming the coacervate interfacial film contains a cationic hectorite nanoplate-shaped particle structure containing a hectorite nanoplate-shaped particle and a cationic surfactant coupled to a surface of the hectorite nanoplate-shaped particle, and an anionic cellulose nanofibril containing an anionic functional group in at least a portion thereof, in which the composite may form the coacervate interfacial film at an interface of an oil phase and a water phase through electrostatic interaction between the cationic surfactant and the anionic functional group.

Abstract: Provided is a pixel driving circuit including a first circuit configured to control, in a data writing mode, a signal related to driving of one or more light-emitting elements, and a second circuit configured to supply, in a driving mode, power to the one or more light-emitting elements based on a signal transmitted from the first circuit.

Abstract: A liquid formulation of a long-acting conjugate of GLP-2 and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 18,630 nmol/mL of a long-acting conjugate, a stabilizer, and a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.5 to 6.5.

Abstract: A liquid formulation of a long-acting conjugate of glucagon, GLP-1, and GIP trigonal agonist, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 920 nmol/mL of a long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 5.0 to 7.0, and 0.5% (w/v) to 10% (w/v) of a sugar alcohol, saccharide, or a combination thereof.

Abstract: A method for improving the solubility of a physiologically active protein or peptide compared to that of a physiologically active protein or peptide which is not conjugated to an immunoglobulin Fc fragment is disclosed. The method includes steps of conjugating the physiologically active protein or peptide to an immunoglobulin Fc fragment. Also disclosed is a composition for improving the solubility of a physiologically active protein or peptide, which contains an immunoglobulin Fc fragment. The composition improves the solubility compared to a composition without an immunoglobulin Fc fragment.

Abstract: A liquid formulation of a long-acting conjugate of glucagon, and a method for preparing the liquid formulation are disclosed. The liquid formulation contains 18 nmol/mL to 936 nmol/mL of a long-acting conjugate, a buffering agent in an amount for maintaining the pH of the liquid formulation in the range of 4.8 to 6.5, and 1.

Abstract: The present invention relates to polyethylene glycol derivatives and use thereof.

Abstract: A deburring tool includes: a body; and a cutting unit provided on an end portion of the body and including a blade part, where a first channel is provided inside the body, and when a fluid supplied from outside of the deburring tool through the first channel is injected into the cutting unit and presses the cutting unit, the cutting unit moves and a degree to which the blade part protrudes outwardly increases.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: The present application relates to: a single base substitution protein; a composition comprising same; and a use thereof.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex prepared by the present invention may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.

Abstract: A deburring tool includes: a body; and a cutting unit provided on an end portion of the body and including a blade part, where a first channel is provided inside the body, and when a fluid supplied from outside of the deburring tool through the first channel is injected into the cutting unit and presses the cutting unit, the cutting unit moves and a degree to which the blade part protrudes outwardly increases.

Abstract: Disclosed is a method for the preparation of a complex in which a physiologically active polypeptide is covalently bonded to an immunoglobulin constant region via a non-peptidyl linker. The method is characterized by the employment of a reducing agent, by which conventional problems of low production yield and modification of the polypeptide can be overcome. The physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be produced with high purity and yield as well as at low cost. Thus, the method is industrially useful. Moreover, by exhibiting a prolonged action profile, the physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be effectively used for developing long-acting formulations of physiologically active polypeptides which have improved drug compliance.

Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.